Clinical Trial Update: Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067) [Phase 1]

View source ↗

Summary

Phase 1 PET study evaluating brain CGRP receptor occupancy after telcagepant administration in migraine patients; trial completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Telcagepant (telcagepant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Migraine | Phase 1 | Status: COMPLETED | Results posted: 2014-10-24